Physician profile
David Howlett
NPI 1760469829
$4,901.62
in general payments reported to CMS, 2019-2025
34 companies · $865 in 2025
The $865 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $437 · 2020: $359 · 2021: $795 · 2022: $638 · 2023: $849 · 2024: $958 · 2025: $865.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,673.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,672.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $872.16 | 2020-2025 | |
| Novo Nordisk INC | $857.11 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $520.69 | 2019-2025 | Breztri, Bevespi Aerosphere, Airsupra |
| Lilly USA, LLC | $416.42 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $343.80 | 2020-2025 | Jardiance |
| Exact Sciences Corporation | $214.32 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Glaxosmithkline, LLC. | $198.04 | 2019-2025 | Shingrix, Arexvy, Bexsero |
| Pfizer INC. | $177.52 | 2023-2025 | |
| Sanofi-Aventis U.S. LLC | $146.26 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $132.53 | 2019-2025 | Capvaxive, Gardasil 9, Gardasil |
| Astellas Pharma US INC | $125.38 | 2019-2024 | Veozah |
| Amgen INC. | $112.43 | 2024-2025 | Krystexxa, Repatha |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $112.12 | 2019-2023 | Xifaxan |
| Teva Pharmaceuticals USA, INC. | $64.49 | 2019-2020 | |
| Mylan Specialty L.P. | $56.26 | 2019-2023 | Yupelri |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $54.74 | 2024-2025 | Gemtesa |
| Abbott Laboratories | $50.29 | 2025 | Freestyle Libre 3 |
| Esperion Therapeutics, INC. | $45.94 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $43.51 | 2020-2022 | |
| Ultragenyx Pharmaceutical INC. | $38.25 | 2019-2023 | |
| Kyowa Kirin, INC. | $36.67 | 2023-2025 | Crysvita |
| Novartis Pharmaceuticals Corporation | $35.74 | 2022 | |
| Amarin Pharma, INC. | $35.07 | 2020-2021 | |
| Kowa Pharmaceuticals America, INC. | $27.48 | 2021 | |
| Baxter Healthcare | $25.28 | 2023 | Hillrom - Carnation Ambulatory Monitor |
| Eisai INC. | $23.66 | 2025 | |
| Phathom Pharmaceuticals, INC. | $19.91 | 2024 | Voquezna |
| Adlon Therapeutics L.P. | $19.61 | 2020 | |
| Medtronic Vascular, INC. | $18.72 | 2020 | |
| Medtronic, INC. | $18.47 | 2021 | |
| Hologic Sales and Service, LLC | $15.19 | 2022 | |
| Cranial Technologies, INC | $14.65 | 2025 | Doc Band |
| Allergan, INC. | $14.63 | 2020 | |
| Janssen Pharmaceuticals, INC | $14.28 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Howlett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.